SC
GILD icon

SummitTX Capital’s Gilead Sciences GILD Stock Holding History

SummitTX Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-74,476
Closed -$8.27M – 803
2025
Q3 		$8.27M Buy
74,476
+6,928
+10% +$787K 0.34% 65
2025
Q2 		$7.49M Buy
67,548
+61,164
+958% +$6.51M 0.32% 67
2025
Q1 		$715K Buy
+6,384
New +$659K 0.03% 464

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SummitTX Capital's GILD Position: Q4 2025 in Review

SummitTX Capital sold out of Gilead Sciences (GILD) in Q4 2025, closing a stake of 74,476 shares — an estimated $8.27M sold.

SummitTX Capital first reported a position in GILD in Q1 2025 and held it in 3 quarters. The position peaked at $8.27M in Q3 2025. 2,215 funds tracked by Wall St. Rank hold GILD as of Q4 2025.

  • SummitTX Capital reported no remaining Gilead Sciences position as of Q4 2025 after selling out during the quarter.
  • SummitTX Capital sold 74,476 Gilead Sciences shares in Q4 2025, an estimated $8.27M.
  • SummitTX Capital first reported a position in Gilead Sciences in Q1 2025 and held it in 3 quarters.
  • SummitTX Capital's Gilead Sciences position peaked at $8.27M in Q3 2025.
  • 2,215 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2025.

Based on SummitTX Capital's 13F filing for Q4 2025, filed 17 Feb 2026.